Last reviewed · How we verify
Investigational mRNA-1273.815
mRNA-1273.815 is an mRNA vaccine encoding modified spike proteins designed to elicit immune responses against SARS-CoV-2 variants.
mRNA-1273.815 is an mRNA vaccine encoding modified spike proteins designed to elicit immune responses against SARS-CoV-2 variants. Used for COVID-19 prevention (variant-updated formulation).
At a glance
| Generic name | Investigational mRNA-1273.815 |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein (variant-specific) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This investigational vaccine uses lipid nanoparticle-formulated mRNA to instruct cells to produce antigen proteins that trigger both humoral and cellular immune responses. The .815 designation indicates a variant-updated formulation targeting emerging SARS-CoV-2 strains beyond the original Wuhan strain. The vaccine aims to provide broader or enhanced protection against circulating variants of concern.
Approved indications
- COVID-19 prevention (variant-updated formulation)
Common side effects
- Injection site pain/erythema
- Fatigue
- Myalgia
- Headache
- Fever
Key clinical trials
- A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational mRNA-1273.815 CI brief — competitive landscape report
- Investigational mRNA-1273.815 updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI